Perspective Article
Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis
Michael K. Lichtman MD,
Marta Otero-Vinas PhD,
Vincent Falanga MD, FACP,
Corresponding Author
Michael K. Lichtman MD
Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Veterans’ Administration, Boston Healthcare System, Division of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Michael K. Lichtman, MD, Assistant Professor of Dermatology and Peter E. Pochi,MD, Junior Chair of Research at Boston University School of Medicine, Boston, MA 02118. Tel: 617-638-5597; Fax: 617-638-5519; Email. [email protected]Search for more papers by this authorMarta Otero-Vinas PhD
Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Department of Systems Biology, The Tissue Repair and Regeneration Laboratory, University of Vic—Central University of Catalonia, Vic, Spain
Search for more papers by this authorVincent Falanga MD, FACP
Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts
Search for more papers by this authorMichael K. Lichtman MD,
Marta Otero-Vinas PhD,
Vincent Falanga MD, FACP,
Corresponding Author
Michael K. Lichtman MD
Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Veterans’ Administration, Boston Healthcare System, Division of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Michael K. Lichtman, MD, Assistant Professor of Dermatology and Peter E. Pochi,MD, Junior Chair of Research at Boston University School of Medicine, Boston, MA 02118. Tel: 617-638-5597; Fax: 617-638-5519; Email. [email protected]Search for more papers by this authorMarta Otero-Vinas PhD
Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Department of Systems Biology, The Tissue Repair and Regeneration Laboratory, University of Vic—Central University of Catalonia, Vic, Spain
Search for more papers by this authorVincent Falanga MD, FACP
Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts
Search for more papers by this authorAbstract
Scar formation, with persistent alteration of the normal tissue structure, is an undesirable and significant result of both wound healing and fibrosing disorders. There are few strategies to prevent or to treat scarring. The transforming growth factor beta (TGF-β) superfamily is an important mediator of tissue repair. Each TGF-β isoform may exert a different effect on wound healing, which may be context-dependent. In particular, TGF-β1 may mediate fibrosis in adults’ wounds, while TGF-β3 may promote scarless healing in the fetus and reduced scarring in adults. Thus, TGF-β3 may offer a scar-reducing therapy for acute and chronic wounds and fibrosing disorders.
References
- 1
Finnson KW,
McLean S,
Di Guglielmo GM,
Philip A. Dynamics of transforming growth factor beta signaling in wound healing and scarring. Adv Wound Care 2013; 2: 195–214.
10.1089/wound.2013.0429 Google Scholar
- 2 Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-β family in wound healing, burns and scarring: a review. Int J Burns Trauma 2012; 2: 18–28.
- 3 Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004; 35: 83–92.
- 4 Attisano L, Wrana JL. Mads and Smads in TGF beta signalling. Curr Opin Cell Biol 1998; 10: 188–94.
- 5 Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 9: 128–39.
- 6 Graycar JL, Miller DA, Arrick BA, Lyons RM, Moses HL, Derynck R. Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and beta 2. Mol Endocrinol Baltim Md 1989; 3: 1977–86.
- 7 Levine JH, Moses HL, Gold LI, Nanney LB. Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol 1993; 143: 368–80.
- 8 Le M, Naridze R, Morrison J, Biggs LC, Rhea L, Schutte BC, et al. Transforming growth factor Beta 3 is required for excisional wound repair in vivo. PLoS One 2012; 7: e48040.
- 9 Chang Z, Kishimoto Y, Hasan A, Welham NV. TGF-β3 modulates the inflammatory environment and reduces scar formation following vocal fold mucosal injury in rats. Dis Model Mech 2014; 7: 83–91.
- 10 Occleston NL, O'Kane S, Laverty HG, Cooper M, Fairlamb D, Mason T, et al. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen 2011; 19 (Suppl. 1): s38–48.
- 11 Kawakami T, Soma Y, Mizoguchi M, Saito R. Immunohistochemical expression of transforming growth factor beta3 in calcinosis in a patient with systemic sclerosis and CREST syndrome. Br J Dermatol 2000; 143: 1098–100.
- 12 Amento EP, Beck LS. TGF-beta and wound healing. Ciba Found Symp 1991; 157: 115–23; discussion 123–9.
- 13 Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83: 4167–71.
- 14 Montesano R, Orci L. Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci USA 1988; 85: 4894–7.
- 15 Peplow PV, Chatterjee MP. A review of the influence of growth factors and cytokines in in vitro human keratinocyte migration. Cytokine 2013; 62: 1–21.
- 16 Kim B-C, Kim HT, Park SH, Cha J-S, Yufit T, Kim S-J, et al. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression. J Cell Physiol 2003; 195: 331–6.
- 17 Pastar I, Stojadinovic O, Krzyzanowska A, Barrientos S, Stuelten C, Zimmerman K, et al. Attenuation of the transforming growth factor beta-signaling pathway in chronic venous ulcers. Mol Med 2010; 16: 92–101.
- 18 Bandyopadhyay B, Fan J, Guan S, Li Y, Chen M, Woodley DT, et al. A “traffic control” role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing. J Cell Biol 2006; 172: 1093–105.
- 19 Iordanskaia T, Nawshad A. Mechanisms of transforming growth factor β induced cell cycle arrest in palate development. J Cell Physiol 2011; 226: 1415–24.
- 20 O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 1997; 29: 63–78.
- 21 Kohama K, Nonaka K, Hosokawa R, Shum L, Ohishi M. TGF-beta-3 promotes scarless repair of cleft lip in mouse fetuses. J Dent Res 2002; 81: 688–94.
- 22 Ferguson MWJ, O'Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 2004; 359: 839–50.
- 23 Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108 (Pt 3): 985–1002.
- 24 Järvinen TAH, Ruoslahti E. Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice. Proc Natl Acad Sci USA 2010; 107: 21671–6.
- 25 Wu L, Siddiqui A, Morris DE, Cox DA, Roth SI, Mustoe TA. Transforming growth factor beta 3 (TGF beta 3) accelerates wound healing without alteration of scar prominence. Histologic and competitive reverse-transcription-polymerase chain reaction studies. Arch Surg 1997; 132: 753–60.
- 26 Lu L, Saulis AS, Liu WR, Roy NK, Chao JD, Ledbetter S, et al. The temporal effects of anti-TGF-beta1, 2, and 3 monoclonal antibody on wound healing and hypertrophic scar formation. J Am Coll Surg 2005; 201: 391–7.
- 27 Ferguson MWJ, Duncan J, Bond J, Bush J, Durani P, So K, et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 2009; 373: 1264–74.
- 28 So K, McGrouther DA, Bush JA, Durani P, Taylor L, Skotny G, et al. Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg 2011; 128: 163–72.
- 29 Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, et al. Autologous bone marrow–derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007; 13: 1299–312.
- 30 Qi Y, Jiang D, Sindrilaru A, Stegemann A, Schatz S, Treiber N, et al. TSG-6 released from intradermally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol 2014; 134: 526–37.
- 31 Moshaverinia A, Xu X, Chen C, Ansari S, Zadeh HH, Snead ML, et al. Application of stem cells derived from the periodontal ligament or gingival tissue sources for tendon tissue regeneration. Biomaterials 2014; 35: 2642–50.
- 32 Arno AI, Gauglitz GG, Barret JP, Jeschke MG. New molecular medicine-based scar management strategies. Burns J Int Soc Burn Inj 2014; 40: 539–51.
- 33 Li P, Liu P, Xiong R-P, Chen X-Y, Zhao Y, Lu W-P, et al. Ski, a modulator of wound healing and scar formation in the rat skin and rabbit ear. J Pathol 2011; 223: 659–71.
- 34 Phan T-T, Lim IJ, Chan S-Y, Tan E-K, Lee S-T, Longaker MT. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma 2004; 57: 1032–7.
- 35 Gary-Bobo M, Nirdé P, Jeanjean A, Morère A, Garcia M. Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr Med Chem 2007; 14: 2945–53.
- 36 McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002; 118: 461–70.
- 37 Santiago B, Gutierrez-Cañas I, Dotor J, Palao G, Lasarte JJ, Ruiz J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005; 125: 450–5.
- 38 Tang B, Zhu B, Liang Y, Bi L, Hu Z, Chen B, et al. Asiaticoside suppresses collagen expression and TGF-??/Smad signaling through inducing Smad7 and inhibiting TGF-??RI and TGF-??RII in keloid fibroblasts. Arch Dermatol Res 2011; 303: 563–72.
- 39 Qi SH, Xie JL, Pan S, Xu YB, Li TZ, Tang JM, et al. Effects of asiaticoside on the expression of Smad protein by normal skin fibroblasts and hypertrophic scar fibroblasts. Clin Exp Dermatol 2008; 33: 171–5.
- 40 Zunwen L, Shizhen Z, Dewu L, Yungui M, Pu N. Effect of tetrandrine on the TGF-β-induced smad signal transduction pathway in human hypertrophic scar fibroblasts in vitro. Burns J Int Soc Burn Inj 2012; 38: 404–13.
- 41 Zhang Z, Garron TM, Li X-J, Liu Y, Zhang X, Li Y-Y, et al. Recombinant human decorin inhibits TGF-beta1-induced contraction of collagen lattice by hypertrophic scar fibroblasts. Burns 2009; 35: 527–37.
- 42 Zhang Z1, Garron T, Li XJ, Liu Y, Zhang X, Li YY XW. Recombinant human decorin inhibits TGF-b1 induced contraction of collagen lattice by keloid fibroblasts. Wounds 2009; 21: 47–56.
- 43 Ono I, Yamashita T, Hida T, Jin HY, Ito Y, Hamada H, et al. Local administration of hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. J Surg Res 2004; 120: 47–55.
- 44 Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006; 17: 54–65.
- 45 Lee WJ, Park SE, Rah DK. Effects of hepatocyte growth factor on collagen synthesis and matrix metalloproteinase production in keloids. J Korean Med Sci 2011; 26: 1081–6.
- 46 Sherriff-Tadano R, Ohta A, Morito F, Mitamura M, Haruta Y, Koarada S, et al. Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism. Mod Rheumatol 2006; 16: 364–71.
- 47 Gragnani A, Warde M, Furtado F, Ferreira LM. Topical tamoxifen therapy in hypertrophic scars or keloids in burns. Arch Dermatol Res 2010; 302: 1–4.
- 48 Carthy JM, Sundqvist A, Heldin A, van Dam H, Kletsas D, Heldin C-H, et al. Tamoxifen inhibits TGF-β-mediated activation of myofibroblasts by blocking non-smad signaling through ERK1/2. J Cell Physiol 2015; 230: 3084–92.
- 49 Mousavi SR, Raaiszadeh M, Aminseresht M, Behjoo S. Evaluating tamoxifen effect in the prevention of hypertrophic scars following surgical incisions. Dermatol Surg 2010; 36: 665–9.
- 50 Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000; 275: 15220–5.
- 51 Ota Y, Kawaguchi Y, Takagi K, Ichida H, Gono T, Hanaoka M, et al. Ghrelin attenuates collagen production in lesional fibroblasts from patients with systemic sclerosis. Clin Immunol 2013; 147: 71–8.
- 52 Winocour S, Vorstenbosch J, Trzeciak A, Lessard L, Philip A. CD109, a novel TGF-β antagonist, decreases fibrotic responses in a hypoxic wound model. Exp Dermatol 2014; 23: 475–9.
- 53 Vorstenbosch J, Gallant-Behm C, Trzeciak A, Roy S, Mustoe T, Philip A. Transgenic mice overexpressing CD109 in the epidermis display decreased inflammation and granulation tissue and improved collagen architecture during wound healing. Wound Repair Regen 2012; 21: 235–46.
- 54 Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2: 134–44.
- 55 Falanga V, Tiegs SL, Alstadt SP, Roberts AB, Sporn MB. Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. J Invest Dermatol 1987; 89: 100–4.
- 56 Perlish JS, Fleischmajer R. Immunological modulation of dermal fibroblasts in scleroderma. Immunol Ser 1989; 46: 605–24.
- 57 Vanneaux V, Farge-Bancel D, Lecourt S, Baraut J, Cras A, Jean-Louis F, et al. Expression of transforming growth factor β receptor II in mesenchymal stem cells from systemic sclerosis patients. BMJ Open 2013; 3. pii: e001890.
- 58 Susol E, Rands AL, Herrick A, McHugh N, Barrett JH, Ollier WE, et al. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. Rheumatol (Oxford) 2000; 39: 1332–6.
- 59 Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 2015; 125: 2795–807.
- 60 Lafyatis R. Transforming growth factor β—at the centre of systemic sclerosis. Nat Rev Rheumatol 2014; 10: 706–19.
- 61 Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16: 544–50.
- 62 Bae E, Kim S-J, Hong S, Liu F, Ooshima A. Smad3 linker phosphorylation attenuates Smad3 transcriptional activity and TGF-β1/Smad3-induced epithelial-mesenchymal transition in renal epithelial cells. Biochem Biophys Res Commun 2012; 427: 593–9.
- 63 Jia L, Ma X, Gui B, Ge H, Wang L, Ou Y, et al. Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition. R Mohanraj, editor. PLoS One 2015; 10: e0117757.
- 64 Nikitorowicz-Buniak J, Denton CP, Abraham D, Stratton R. Partially evoked epithelial-mesenchymal transition (EMT) is associated with increased TGFβ signaling within lesional scleroderma skin. C Feghali-Bostwick, editor. PLoS One 2015; 10: e0134092.
Citing Literature
